Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cationic complex liposome influenza vaccine as well as preparation method and application method thereof

A technology of cationic complexes and cationic liposomes, which is applied in the field of nanomaterial technology and the field of vaccines, can solve the problems of many side effects, difficult immune response, poor safety, etc., and achieve the effect of promoting antigen uptake

Inactive Publication Date: 2021-07-23
NINGXIA MEDICAL UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, influenza virus split vaccines and inactivated vaccines are widely used, but their production process is complicated and the production cost is high. Poor, many side effects, large inoculation dose, weak immunogenicity, difficult to produce efficient protective effect on the body
Compared with traditional vaccines, new-generation subunit vaccines, synthetic peptide vaccines, and nucleic acid vaccines have improved safety, but they are still difficult to induce effective immune responses due to their small molecules and weak immunogenicity. Therefore, further development of more efficient influenza vaccines is urgently needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cationic complex liposome influenza vaccine as well as preparation method and application method thereof
  • Cationic complex liposome influenza vaccine as well as preparation method and application method thereof
  • Cationic complex liposome influenza vaccine as well as preparation method and application method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Embodiment 1: film dispersion method prepares DDA-DSPC-PEG cationic liposome influenza vaccine

[0049] Precisely weigh cationic liposomes (dimethyl dioctadecyl ammonium DDA) and immunomodulators (distearoyl phosphatidylcholine DSPC, distearoyl phosphatidylethanolamine-polyethylene glycol 2000DSPE) of the prescription amount -PEG2000), above-mentioned DDA-DSPC-PEG molar ratio 4:15:1, is placed in 50ml round bottom flask, adds 2ml chloroform-methanol solution to dissolve (V 氯仿 :V 甲醇 =9:1), vortexed for 1 min and then evaporated in a constant temperature water bath at 37°C for 20 min on a rotary evaporator. After the organic solvent was evaporated, a lipid film was visible at the bottom of the round bottom flask. At this time, nitrogen gas was filled for 2 minutes to remove the residual organic solvent.

[0050] Then add a certain amount of Tris buffer solution (concentration: 10mmol / L, pH7.4) into the round bottom flask, and hydrate in a 65°C water bath for 40min to pr...

Embodiment 2

[0053] Embodiment 2: film dispersion method prepares DDA-DSPC cationic liposome influenza vaccine

[0054] Precisely weigh cationic liposomes (dimethyl dioctadecyl ammonium DDA) and immunomodulator (distearoylphosphatidylcholine DSPC) of prescription quantity, above-mentioned DDA-DSPC molar ratio 1:4, place in In a 50ml round bottom flask, add 2ml of chloroform-methanol solution to dissolve (V 氯仿 :V 甲醇 =9:1), vortexed for 1 min and then evaporated in a constant temperature water bath at 37°C for 40 min on a rotary evaporator. After the organic solvent was evaporated, a lipid film was visible at the bottom of the round bottom flask. At this time, nitrogen gas was filled for 2 minutes to remove the residual organic solvent.

[0055] Add a certain amount of Tris buffer solution (concentration is 5mmol / L, pH7.4) , and hydrated in a water bath at 65°C for 20 minutes to prepare DDA-DSPC blank liposomes.

[0056] Add the influenza vaccine stock solution to the DDA-DSPC blank lip...

Embodiment 3

[0058] Embodiment 3: film dispersion method prepares DDA-DSPC-TPGS cationic liposome influenza vaccine

[0059] Precisely weigh cationic liposomes (dimethyl dioctadecyl ammonium DDA) and immunomodulators (distearoylphosphatidylcholine DSPC, vitamin E polyethylene glycol succinate TPGS) of prescription quantity, above-mentioned DDA-DSPC-TPGS molar ratio is 4:15:1, is placed in 50ml round bottom flask, adds 2ml chloroform-methanol solution to dissolve (V 氯仿 :V 甲醇 =9:1), vortexed for 1 min and then evaporated in a constant temperature water bath at 37°C for 20 min on a rotary evaporator. After the organic solvent was evaporated, a lipid film was visible at the bottom of the round bottom flask. At this time, nitrogen gas was filled for 2 minutes to remove the residual organic solvent.

[0060] Then add a certain amount of PBS buffer solution (concentration: 30mmol / L, pH7.4) into the round bottom flask, and hydrate in a 65°C water bath for 20min to prepare DDA-DSPC-TPGS blank lip...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a cationic complex liposome influenza vaccine as well as a preparation method and an application method thereof. With cationic liposome as an immune carrier and an adjuvant, the influenza vaccine comprises an immunomodulator and encapsulates an influenza vaccine antigen. The constructed cationic complex liposome influenza vaccine is 200-700nm in particle size, 5-40mV in Zeta potential, 30-90% in encapsulation efficiency, and 1-10% in drug loading capacity. The prepared cationic complex liposome influenza vaccine can significantly promote antigen uptake of dendritic cells, stimulate activation and maturation of DCs, and further cause immune response. The influenza vaccine is used for immunotherapy through intramuscular injection, subcutaneous injection or nasal mucosal administration, wherein the mucosal immune response level and the cellular immune response level of the organism are effectively enhanced through nasal mucosal administration. The influenza vaccine has a wide application prospect in influenza prevention.

Description

technical field [0001] The invention belongs to the technical field of nanomaterials and the field of vaccines, and in particular relates to a cationic complex liposome influenza vaccine and a preparation method and application method thereof. Background technique [0002] Influenza is an acute respiratory infectious disease caused by influenza virus, which seriously endangers human health. So far, the most effective way to prevent influenza is still to get vaccinated. At present, influenza virus split vaccines and inactivated vaccines are widely used, but their production process is complicated and the production cost is high. Poor, many side effects, large vaccination dose, weak immunogenicity, it is difficult to produce efficient protective effect on the body. Compared with traditional vaccines, new-generation subunit vaccines, synthetic peptide vaccines, and nucleic acid vaccines have improved safety, but they are still difficult to induce effective immune responses due...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/145A61K39/39A61P31/16
CPCA61K39/12A61K39/39A61P31/16C12N2760/16134A61K2039/55555A61K2039/543A61K2039/54A61K2039/575A61K2039/57
Inventor 杨建宏郭珏铄买亚萍于蕊李莉侯延辉
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com